Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Mesothelioma × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 6 Carcinoma, Non-Small-Cell Lung 3 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lung Neoplasms 1 Kidney Neoplasms 1 Fallopian Tube Neoplasms 1 Cystadenocarcinoma, Serous 1 Colorectal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinosarcoma 1 Breast Neoplasms 1 Adenocarcinoma, Mucinous 1

Interventions

pembrolizumab 9 Pemetrexed 7 Cyclophosphamide 6 Cisplatin 5 Carboplatin 5 fludarabine 4 Nivolumab 4 Ipilimumab 4 Drug Therapy 2 Bevacizumab 2 tremelimumab 1 tocilizumab 1 tazemetostat 1 spartalizumab 1 rebastinib 1 poly ICLC 1 pevonedistat 1 osimertinib 1 milademetan 1 fludarabine phosphate 1 epacadostat 1 durvalumab 1 defactinib 1 atezolizumab 1 aldesleukin 1 Vorinostat 1 Thiostrepton 1 Tablets 1 Plicamycin 1 Pentostatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01211275 2017-02-28

N08CPA

The Netherlands Cancer Institute

Phase 1/2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡